myelodysplastic syndrome


Also found in: Thesaurus, Medical, Acronyms, Encyclopedia, Wikipedia.

myelodysplastic syndrome

n.
Any of a group of disorders characterized by the abnormal proliferation of bone marrow cells that are precursors to blood cells. It is often associated with abnormalities of blood cells such as anemia and leukopenia.
References in periodicals archive ?
Boston Biomedical is evaluating DSP-7888 in phase 1 and 2 studies for patients with pediatric high grade gliomas, myelodysplastic syndrome, recurrent or progressive glioblastoma, and other malignant cancers.
Opsona Therapeutics Ltd (Opsona), an innate immune drug and development company focused on novel therapeutic approaches to treat oncology, autoimmune and other inflammatory diseases, revealed on Tuesday that it has received orphan drug designation (ODD) from the US Food and Drug Administration for OPN-305 in the rare disease myelodysplastic syndromes (MDS).
Additionally, the report provides an overview of key players involved in therapeutic development for Myelodysplastic Syndrome and features dormant and discontinued projects.
In 6 patients having myelodysplastic syndrome 3 patients were diagnosed with refractory anaemia with excess blasts type-1, 2 patients with refractory cytopenia with multi lineage dysplasia and 1 patient with childhood myelodysplasia.
The report reviews key players involved in the therapeutics development for Myelodysplastic Syndrome and enlists all their major and minor projects
Myelodysplastic syndrome (MDS) is a heterogenous group of hematopoietic stem cell disorders that are multifactorial in their etiology and often difficult to distinguish from hematological benign diseases with unilineage or multilineage cytopenia such as aplastic anemia (AA) both in clinic and laboratory.
Aortic valve replacement in a patient with pancytopenia secondary to myelodysplastic syndrome.
Fighting back tears on several occassions, Robin Roberts said her myelodysplastic syndrome was caused by her treatment for breast cancer, which she beat five years ago.
Predicting survival and leukemic evolution in patients with myelodysplastic syndrome.
According to Dr John Pagel, a transplant oncologist and assistant member of the Hutchinson Center's Clinical Research Division, patients over the age of 50 with active, advanced leukemia and myelodysplastic syndrome pose the most difficult treatment challenges because standard transplant therapy rarely works.
Proposals for the classification of the myelodysplastic syndrome.